Lucentis represents the first FDA-approved treatment for diabetic retinopathy patients with or without diabetic macular edema.
The FDA previously approved the drug to treat various eye conditions, including wet age-related macular degeneration, diabetic macular edema and myopic choroidal neovascularization.
More articles on supply chain:
Global pharmerging market to reach $1.4B by 2025
FDA OKs Tecentriq for advanced bladder cancer
Bristol-Myers will license drugs to Biogen, Roche for $470M
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.